1 / 12

Management of Substance Use Disorder

Management of Substance Use Disorder. Module P: Addiction-Focused Pharmacotherapy. Patient with substance use disorder (SUD) (A). Is Opioid agonist therapy (OAT) appropriate for and acceptable to the patient? (C). Is the patient opioid dependent? (B).

beverly-nunez
Download Presentation

Management of Substance Use Disorder

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy

  2. Patient with substance use disorder (SUD) (A) Is Opioid agonist therapy (OAT) appropriate for and acceptable to the patient? (C) Is the patient opioid dependent? (B) Initiate or continue opioid agonist therapy (D)

  3. Initiate or continue opioid agonist therapy • Available since 1960’s BUT confined to Opioid Treatment Programs, under federal and state controls. • Most effective medication in treating addiction, when used in well-run treatment program.

  4. Indications for OAT • Opioid dependence > 1 year • 2 or more unsuccessful opioid detoxification episodes within a 12-month period • Relapse to opioid dependence within 2 years from OAT discharge

  5. Is naltrexone therapy Appropriate for and Acceptable to the patient? (E) Is the Patient Opioid Dependent? (B) Assure patient is detoxified and Opioid free before continuing (F) Initiate naltrexone for opioid Dependence with patient Education and monitoring (G) Arrange for detoxification if Indicated See Module S

  6. Naltrexone has no positive psychoactive effects. Some highly motivated patients can be successful using naltrexone therapy.

  7. Subpopulations with better prognosis for response include: • Patients highly motivated for abstinence • Patients in the criminal justice system, with monitored administration • Health care workers with employment-related monitoring

  8. Indications for Naltrexone • Ability to achieve at least 7-10 days of abstinence to rule out the need for detoxification

  9. Is the patient alcohol Dependent? (H) Is Pharmacotherapy for Alcohol Dependence Indicated? (I) Initiate pharmacotherapy for Alcohol dependence with patient Education monitoring (J)

  10. Indications for Naltrexone in the Treatment of Alcohol Dependence • Ability to achieve at least 3-5 days of abstinence to rule out the need for detoxification • Drinking within the past 30 days and/or reports of craving • Most effective when the patient is engaged in addiction-focused counseling

  11. Indications for Disulfiram in the Treatment of Alcohol Dependence • Alcohol dependence with: • Abstinence >24 hours • Combined cocaine and alcohol • Failure of or contraindication to naltrexone • Previous response to disulfiram

  12. Naltrexone in the Treatment of Alcohol Dependence 1.0 0.8 0.6 0.4 Naltrexone HCl (N=35) Placebo (N=35) 0.2 0.0 0 1 2 3 4 5 6 7 8 9 10 11 12 No. of Weeks Receiving Medication Volpicelli et al. Arch Gen Psychiatry. 1992;49:876-880

More Related